A prospective cardiovascular population study used in genetic epidemiology. The Copenhagen City Heart Study

Scandinavian Journal of Clinical and Laboratory Investigation, Supplement

Volumn 56, Issue 226, 1996, Pages 65-71

  Nordestgaard, Børge G ^a   Agerholm Larsen, Birgit ^a   Wittrup, Hans H ^a   Tybjærg Hansen, Anne ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

angiotensin converting enzyme gene polymorphism; glucose; high density lipoprotein; ischemic heart disease; lipoprotein lipase; mutation; stroke; triglycerides

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; LIPOPROTEIN LIPASE;

AGE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DENMARK; DYSLIPIDEMIA; FEMALE; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; INFORMATION PROCESSING; MALE; MUTATION; PHENOTYPE; PRIORITY JOURNAL; COHORT ANALYSIS; GENE LIBRARY; GENETICS; HEART MUSCLE ISCHEMIA; PROSPECTIVE STUDY;

CARDIOVASCULAR DISEASES; COHORT STUDIES; DENMARK; FEMALE; GENE LIBRARY; HUMANS; MALE; MUTATION; MYOCARDIAL ISCHEMIA; PROSPECTIVE STUDIES;

EID: 0030340911     PISSN: 0085591X     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365519609168300     Document Type: Article

References (10)

1. Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994; 15:1300-31.
2. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastitin Survival Study (4S). Lancet 1994;344: 1383-9.
3. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New Engl J Med 1995;333:1301-7.
4. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335:827-38.
5. Appleyard M, Hansen AT, Jensen G, Schnohr P, Nyboe J. The Copenhagen City Heart Study. Østerbroundersøgelsen. A book of tables with data from the first examination (1976-78) and a five year follow-up (1981-83). The Copenhagen City Heart Study Group. Scand J Soc Med 1989;Suppl 41:1-160.
6. 188 → Glu mutation in the lipoprotein lipase gene: screening among 1000 heart patients and 5400 persons from the general population (The Copenhagen City Heart Study). Atherosclerosis 1994:109:205.
7. Brunzell J. Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome. In: Scriver C, Beaudet A, Sly W, Valle D, eds. The metabolic and molecular bases of inherited disease, 7th ed. New York: McGraw-Hill Inc. 1995:1913-32.
8. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992;359: 641-4.
9. Lindpaintner K, Pfeffer MA, Kreutz R, Stampfer MJ, Grodstein F, LaMotte F, et al A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. New Engl J Med 1995;332:706-11.
10. Agerholm-Larsen B, Nordestgaard BG, Steffensen R, Sørensen TLA, The Copenhagen City Heart Study Group, Tybjærg-Hansen A. The angiotensin-converting-enzyme gene polymorphism fails to predict coronary heart disease in a case-cohort study of 7300 individuals. Circulation 1995;92, Suppl. 1:1 800.